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Abstract: Alzheimer’s disease (AD) is characterized by extracellular accumulation of 
amyloid-β peptide (Aβ), generated by proteolytic processing of the amyloid precursor 
protein (APP) by β- and γ-secretase. Aβ generation is inhibited when the initial ectodomain 
shedding is caused by α-secretase, cleaving APP within the Aβ domain. Therefore, an 
increase in α-secretase activity is an attractive therapeutic target for AD treatment. APP 
and the APP-cleaving secretases are all transmembrane proteins, thus local membrane lipid 
composition is proposed to influence APP processing. Although several studies have 
focused on γ-secretase, the effect of the membrane lipid microenvironment on α-secretase 
is poorly understood. In the present study, we systematically investigated the effect of fatty 
acid (FA) acyl chain length (10:0, 12:0, 14:0, 16:0, 18:0, 20:0, 22:0, 24:0), membrane polar 
lipid headgroup (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine), 
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saturation grade and the FA double-bond position on α-secretase activity. We found that  
α-secretase activity is significantly elevated in the presence of FAs with short chain length 
and in the presence of polyunsaturated FAs, whereas variations in the phospholipid 
headgroups, as well as the double-bond position, have little or no effect on α-secretase 
activity. Overall, our study shows that local lipid membrane composition can influence  
α-secretase activity and might have beneficial effects for AD. 




Alzheimer’s disease (AD) is the most common cause of dementia among neurodegenerative 
diseases in the industrialized nations and is characterized by a progressive memory loss and cognitive 
failure. One of the main pathological hallmarks of AD is the aggregation of a small peptide, called 
amyloid-β (Aβ), as senile plaques in the brains of affected individuals [1,2]. Aβ is generated by 
sequential proteolytic processing of the amyloid precursor protein (APP), a large type-I 
transmembrane protein [3]. In the amyloidogenic pathway, APP is first cleaved by the transmembrane 
aspartic protease β-secretase BACE1 [4,5], generating the N-terminus of Aβ followed by a second 
cleavage at the γ-cleavage site within the transmembrane domain of APP, releasing toxic Aβ  
peptides [6,7]. The γ-secretase has been identified as a protein complex, consisting of at least four 
transmembrane proteins, presenilin1 (PS1) or presenilin2 (PS2), nicastrin, anterior pharynx defective 1 
(APH1a or APH1b) and presenilin enhancer 2 (PEN2) [8–11]. In an alternative non-amyloidogenic 
pathway, APP can be processed by α-secretases, cleaving APP within the Aβ domain, resulting in a 
non-toxic peptide [12]. As the α- and β-secretases are assumed to compete for APP as a substrate, an 
increase in α-secretase cleavage is discussed to be a therapeutic approach for AD [13]. The  
α-secretases have been identified as members of the ADAM family (a disintegrin and 
metalloproteinase) [14–17], type-I transmembrane proteins of the metzincin family, requiring a zinc 
ion for their proteolytic activity. As APP itself and the secretases involved in APP cleavage are all 
integral membrane proteins, lipid composition of cellular membranes is discussed as influencing the 
proteolytic processing of APP [18–21], either by directly affecting secretase activities, or by 
modulating the dynamics and accessibility of APP to the cleaving proteases [22–24]. Moreover, it has 
been shown that the flexible transmembrane domain of APP is able to bind cholesterol [25]. Several 
lipids, including cholesterol, sphingomyeline and gangliosides, have been shown to alter 
amyloidogenic APP processing [22,26–31]. Furthermore, accumulating evidences suggest that 
neuronal phospholipid composition is altered in AD [32–34] and a recent study addressed the influence 
of membrane phospholipids on amyloidogenic processing of APP [35]. However, the effect of 
different phospholipids on non-amyloidogenic APP processing is poorly investigated. Phospholipids 
belong to glycerol-based lipids, which are characterized by a glycerol-backbone. The sn-1 and sn-2 
position of the glycerol-backbone are esterified to a fatty acid (FA), while the sn-3 position is 
esterified to a phosphate group, which in turn is esterified to a polar headgroup. Phospholipids can 
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therefore vary in different attributes, e.g., FA acyl chain length, saturation grade, double-bond position 
and in the polar lipid headgroup, greatly influencing the physicochemical properties of a specific 
phospholipid. As phospholipids determine the local microenvironment of transmembrane proteins and 
influence e.g., membrane fluidity, which is important for lateral movement of transmembrane proteins 
within the phospholipid bilayer, we systematically investigated the effect of specific phospholipids on 
α-secretase activity in different in vitro systems and in living cells. 
2. Results and Discussion  
2.1. Effect of FA Carbon Chain Length on α-Secretase Activity 
In order to evaluate whether FA carbon chain length affects non-amyloidogenic processing of APP, 
we analyzed saturated FA chains of increasing carbon chain length with phosphatidylcholine (PC) as 
constant headgroup (PC10:0, PC12:0, PC14:0, PC16:0, PC18:0, PC20:0, PC22:0, PC24:0). In a first 
step, we prepared purified membranes of the human neuroblastoma cell line SH-SY5Y containing the 
membrane protein secretases involved in APP processing, incubated them with the PC phospholipids 
mentioned above, and measured α-secretase activity directly by in vitro processing of a fluorogenic  
α-secretase substrate. Uptake of the phospholipids was controlled by mass spectrometry (Figure S5). 
As PC18:0 revealed no effect on α-secretase activity compared to purified SH-SY5Y membranes 
incubated with the solvent ethanol (Figure S1), and PC18:0 is one of the major PC species in the 
membrane (Table S5), PC18:0 represents the control FA throughout our study addressing FA carbon 
chain length. PC10:0, PC12:0 and PC14:0 increased α-secretase activity in purified membranes of  
SH-SY5Y wildtype (wt) cells (Figure 1A). However, statistical significance was only  
obtained for PC12:0 (PC10:0: 127.7% ± 2.2%, p = 0.123; PC12:0: 144.0% ± 9.3%, p = 0.002;  
PC14:0: 128.0% ± 11.9%, p = 0.116), whereas PC16:0, PC20:0, PC22:0 and PC24:0 showed no effect 
(Figure 1A, Table S1), thereby indicating that PC10:0, PC12:0 and PC14:0 increase α-secretase 
activity. Additionally, we evaluated the effect of increasing FA chain length on α-secretase activity in 
context of living cells. SH-SY5Y wt cells were cultured for 8 + 16 h in the presence of the 
phospholipids mentioned earlier (final concentration 10 µM) and α-secretase activity was measured by 
adding 10 µM phospholipid and 10 µM fluorogenic α-secretase substrate to the 96-well cell culture 
plate. In line with the efficient uptake of the phospholipids in purified membranes, the phospholipids 
were significantly increased after incubation in living SH-SY5Y cells. Uptake controls were shown for 
PC12:0 and PC18:0 (Figure S5). As already observed for purified SH-SY5Y wt membranes, PC10:0 
and PC12:0 increased α-secretase activity (PC10:0: 124.8% ± 1.3%; p < 0.001; PC12:0: 126.9 ± 1.3%, 
p < 0.001) and PC16:0, PC20:0, PC22:0 and PC24:0 had no significant effect (Figure 1A, Table S1). 
However, as a slight difference compared to the results obtained from purified membranes, PC14:0 did 
not increase α-secretase activity in living cells (Figure 1A, Table S1). The discrepancy of the effect on 
α-secretase activity obtained for PC14:0 in purified membranes and living cells might be caused by 
additional factors present in a living system, e.g., altered gene expression or protein stability of  
α-secretase in the presence of PC14:0. Combining the α-secretase measurements of neuroblastoma  
SH-SY5Y wt cells, including purified membranes and living cells, revealed significance for PC10:0, 
PC12:0 and PC14:0 (combined data: PC10:0: 126.0% ± 1.3%, p < 0.001; PC12:0: 129.9% ± 2.4%,  
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p < 0.001; PC14:0: 114.0 ± 6.7, p = 0.001) (Table S1), indicating that FA acyl chains with short chain 
length increase non-amyloidogenic processing of APP. Interestingly, for γ-secretase, it has been 
recently reported that increasing the FA carbon chain length (14, 16, 18 and 20) elevates γ-secretase 
activity [35], peaking at lengths of 18 and 20 carbons. The diverse effects of FAs with increasing 
carbon chain length on α- and γ-secretase activity might be caused by the presence of membrane 
microdomains with defined lipid and protein compositions. Detergent-resistant membrane 
microdomains, also called lipid rafts [36], containing higher levels of cholesterol and sphingolipids, 
are implicated in amyloidogenic APP processing [37]. The β-secretase BACE1 and amyloidogenic  
γ-secretase cleavage have been shown to be associated with lipid rafts [38–40]. Remarkably, lipid rafts 
also contain higher levels of FAs with 20 and 22 carbons [41]. In contrast to the involvement of lipid 
rafts in β- and γ-secretase processing of APP, the α-secretase mediated non-amyloidogenic processing 
is discussed to occur in non-raft regions of the membrane [42–44], which could be a possible 
explanation why phospholipids with longer FA carbon chains affect γ- but not α-secretase activity. 
Figure 1. Effect of FA carbon chain length on α-secretase activity. (A) Purified 
membranes of SH-SY5Y wildtype (wt) cells and living SH-SY5Y wt cells were exposed to 
phospholipids containing FAs of increasing carbon chain length. For purified membranes, 
25 µM phospholipid was used; living cells were exposed 8 + 16 h to 10 µM phospholipid. 
The α-secretase activity was measured by adding a fluorogenic α-secretase substrate and 
fluorescence was measured using a Safire2 Fluorometer; (B) Purified membranes of human 
post mortem brains were incubated with 50 µM PC12:0 or PC18:0. The α-secretase activity 
was determined as described for A; (C) Purified α-secretase ADAM10 was incubated with 
25 µM PC12:0 or PC18:0 in the presence of human brain lipid extract. The α-secretase 
activity was determined as described for A. (A,B,C) All quantified data represent an 
average of at least three independent experiments. Error bars represent standard deviation 
of the mean. Asterisks show the statistical significance (* p ≤ 0.05; ** p ≤ 0.01 and  
*** p ≤ 0.001). 
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As phospholipid PC12:0 showed the strongest effect on α-secretase activity in purified membranes 
of SH-SY5Y wt cells and in living cells, we analyzed whether PC12:0 also increases non-amyloidogenic 
APP processing in the lipid environment of human brain. Therefore, purified membranes of nine 
healthy human post mortem brains were prepared and pooled, and α-secretase activity was measured in 
the presence of PC12:0. Indeed, PC12:0 also significantly elevated α-secretase activity in purified 
membranes of human post mortem brains compared to the control PC18:0 (PC12:0: 141.9% ± 7.6%,  
p = 0.004) (Figure 1B; Table S1). The increase was nearly identical as observed for purified SH-SY5Y 
wt membranes (PC12:0: 144.0% ± 9.3%, p = 0.002) (Figure 1A). Because these results suggest, that 
PC12:0 directly increases α-secretase activity, we further analyzed the effect of PC12:0 on purified 
enzyme. As the α-secretase ADAM10 has been recently shown to be the physiologically relevant  
α-secretase in neurons [45], we selected ADAM10 to determine the effect of phospholipids on purified 
α-secretase throughout this study. Purified ADAM10 was incubated with PC12:0 in the presence of 
human post mortem brain lipid extract to reconstitute brain lipid environment. Also in this 
experimental approach, ADAM10 activity was significantly increased in the presence of PC12:0 
compared to PC18:0 (PC12:0: 132.0% ± 9.6%; p = 0.011) (Figure 1C, Table S1), validating that 
PC12:0 directly influences α-secretase activity. However, although ADAM10 is discussed to be the 
major α-secretase in neurons [45], further α-secretase candidates, e.g., ADAM17 and ADAM9 [14,16], 
might be affected by PC12:0. This is a rather likely scenario, as we obtained for purified membranes of 
SH-SY5Y wt cells and purified membranes of human post mortem brains, where total α-secretase and 
not exclusively ADAM10 activity is determined, an even stronger increase in α-secretase activity. 
However, our data suggest that ADAM10 is the α-secretase candidate mostly affected by shorter FA 
acyl chain length.  
2.2. Variations in the Phospholipid Headgroup on α-Secretase Activity 
Beside FA carbon chain length the polar lipid headgroups of membrane phospholipids might affect 
non-amyloidogenic APP processing. As we observed increased α-secretase activity in the presence of 
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PC10:0, PC12:0 and PC14:0, we examined whether changing the polar lipid headgroup to 
phosphatidylethanolamine (PE) or phosphatidylserine (PS) might additionally modulate the observed 
effect of short FA acyl chain length on α-secretase activity. In accordance with the analysis of the FA 
carbon chain length, we first measured α-secretase activity in purified membranes of SH-SY5Y wt 
cells exposed to different phospholipids, having a constant FA chain length (12:0 or 14:0) but variable 
headgroups (PC, PE, PS). No significant alterations in α-secretase activity were observed for PE12:0 
and PE14:0 compared to PC12:0 or PC14:0 as control (Figure 2A, Table S2), indicating that a change 
in the phospholipid headgroup from PC to PE does not affect non-amyloidogenic α-secretase cleavage 
of APP. In contrast, changing PC to PS revealed some influence on α-secretase activity. However, 
there was no consistent effect on α-secretase activity in all experimental approaches as that observed 
for the FA acyl chain length. In detail, for PS14:0, we found a slight but nonetheless significant, 
increase in α-secretase activity in purified SH-SY5Y wt membranes, as compared to PC14:0  
(PS14:0: 116.2% ± 3.1%, p = 0.001) (Figure 2A, Table S2). On the other hand, for PS12:0 no effect 
was observed, thereby indicating that the altered α-secretase activity found for PS14:0 is not only 
mediated by the variation in the phospholipid headgroup from PC to PS, but is also dependent on the 
FA chain length esterified to the PS phospholipid. Therefore we decided to calculate the effects on  
α-secretase activity in purified SH-SY5Y wt membranes observed for variable polar lipid headgroups 
independent of FA chain length. Indeed statistical analysis revealed no significant alterations on  
α-secretase activity for PE and PS compared to PC (PE: 99.7% +/− 1.0%, p = 1.000;  
PS: 102.0% ± 4.5%, p = 0.936) (Table S2), suggesting that a change in the polar headgroup alone does 
not affect α-secretase activity.  
Figure 2. Effect of the phospholipid headgroup on α-secretase activity. Phospholipids 
having a constant FA chain length (12:0 and 14:0) but variable headgroups (PC, PE, PS) 
were incubated on (A) purified membranes of SH-SY5Y wt cells (B) living SH-SY5Y wt 
cells (C) purified membranes of human post mortem brains. (A,B,C) Phospholipid 
concentration, determination of α-secretase activity, illustration and statistical significance 
as described for Figure 1. 
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To further elucidate this, we analyzed the influence of variable phospholipid headgroups on  
α-secretase activity in living SH-SY5Y wt cells. In accordance to the results obtained with purified 
SH-SY5Y wt membranes, changing the phospholipid headgroup from PC to PE had no significant 
effect on α-secretase activity (Figure 2B, Table S2). In contrast to the results obtained with purified 
membranes of SH-SY5Y wt cells, PS12:0 significantly decreased α-secretase activity in living cells 
(PS12:0: 83.8% ± 1.6%, p = 0.003), whereas PS14:0 showed no significant effect compared to the 
corresponding PC phospholipids (Figure 2B, Table S2). Although a change in the polar lipid 
headgroup from PC to PS also seems to affect α-secretase cleavage of APP in living cells, at least for 
PS12:0, one has to take into consideration that, compared to the results obtained with purified 
membranes of SH-SY5Y wt cells, a significant effect was observed for chain length 12:0 and not for 
chain length 14:0 and α-secretase activity was reduced and not elevated. For that reason, from our 
results we cannot conclude whether a change from PC to PS per se in fact influences α-secretase 
activity and further experiments have to be done to address this topic. However, statistical analysis of 
the α-secretase measurements obtained for PE and PS independent of FA chain length in living cells 
again revealed no significant alterations on α-secretase activity (Table S2), suggesting that variations 
in the polar lipid headgroup independent of FA chain length might not affect α-secretase activity. Our 
hypothesis that a change in the phospholipid headgroup has no or only minor effects on α-secretase 
activity was also supported when purified membranes of human post mortem brains were exposed to 
the aforementioned phospholipids. Neither a change from PC to PE nor a change to PS in the 
phospholipid headgroup significantly affected α-secretase activity (Figure 2C, Table S2). The lack of an 
α-secretase effect when human brain membranes instead of SH-SY5Y wt membranes were incubated 
with PS14:0 might be explained by analyzing the PS to PC ratio in both membranes. TLC analysis of 
purified membranes (SH-SY5Y wt cells and human post mortem brains) revealed that the PS:PC ratio 
is lower in SH-SY5Y wt membranes compared to human brain membranes (Figure S2). Therefore, 
changing the phospholipid headgroup from PC to PS should have a more pronounced effect in  
SH-SY5Y wt cells compared to human brain membranes, as we were able to observe. This result 
indicates that the influence of a single phospholipid on the activity of membrane-imbedded enzymes 
Int. J. Mol. Sci. 2013, 14 5886 
 
 
strongly depends on the local lipid microenvironment. As Aβ deposition is a crucial event in AD and 
α-seretase cleavage prevents the formation of Aβ by forming a non-toxic peptide [12], we conclude 
from our results that changes in the phospholipid headgroup of phospholipid species with short FA 
acyl chain length have no significant effects on α-secretase activity in the lipid environment of human 
brain. Nevertheless, our results do not rule out that variations in the phospholipid headgroup might 
play a role in AD by affecting other molecular pathways besides α-secretase activity. Several studies 
addressed levels of the major membrane phospholipids in AD post mortem brains. PE and 
phosphatidylinositol (PI) levels have been reported to be significantly decreased in AD  
brains [33,34,46,47], whereas PS phospholipids are increased [33]. For PC Nitsch et al. reported a 
significant decrease in AD brains [47], whereas PC was unaffected in the study by Wells et al. [33]. In 
addition, mixtures of different phospholipid headgroup types, including PC, PE, PS, PI and 
phosphatidic acid (PA) have been shown to alter γ-secretase cleavage in vitro [19,35]. Furthermore, 
recently Nesic et al. reported, that α-secretase non-amyloidogenic APP processing is increased when 
PE synthesis was inhibited in mammalian HEK293 cells whereas γ-secretase cleavage of APP is 
reduced, resulting in decreased Aβ levels [48].  
2.3. Effect of FA Saturation on α-Secretase Activity 
Another important feature of membrane phospholipids is the saturation grade of the FA acyl chains. 
In addition to FA chain length, the FA saturation grade strongly affects membrane fluidity, which is 
important for membrane-dependent cellular functions, e.g., cell signaling, transmembrane protein 
function, lateral diffusion of membrane proteins within the membrane, protein–lipid interactions and 
vesicle formation [49]. To investigate whether FA acyl chain saturation of phospholipids influences 
the proteolytic activity of α-secretase, we analyzed monounsaturated and polyunsaturated FA chains 
esterified to a PC glycerol-backbone compared to saturated stearic acid (PC18:0, PC18:1, PC18:2, 
PC18:3, PC20:4, PC20:5, PC22:6). Moreover, these FAs represent the most dominant species found in 
brain (Table S5). Treatment of purified SH-SY5Y wt membranes with oleic acid (PC18:1 ∆9-cis), 
linoleic acid (PC18:2), linolenic acid (PC18:3), arachidonic acid (AA, PC20:4) and docosahexaenoic 
acid (DHA, PC22:6) showed no significant changes in α-secretase activity compared to the control 
phospholipid PC18:0 (Figure 3A, Table S3). FA side chain eicosapentaenoic acid (EPA, PC20:5) 
significantly elevated α-secretase activity (EPA/PC20:5: 123.1% ± 7.6%, p = 0.005) (Figure 3A,  
Table S3). Exposing living SH-SY5Y wt cells to the aforementioned phospholipids (final 
concentration 10 µM) revealed significantly increased α-secretase activity in the presence of 
arachidonic acid, EPA and DHA, compared to control PC18:0 (AA/PC20:4: 124.7% ± 2.0%,  
p = 0.001; EPA/PC20:5: 140.1% ± 14.2%, p < 0.001; DHA/PC22:6: 136.8% ± 2.2%, p < 0.001) 
(Figure 3A, Table S3). Interestingly, in living cells, α-secretase activity was elevated with an 
increasing number of double bonds within the acyl chains with the strongest increase for EPA and 
DHA (Figure 3A), indicating that EPA and DHA are potent stimulators of non-amyloidogenic APP 
processing in a living system. Calculating all α-secretase measurements for SH-SY5Y wt cells, 
including purified membranes and living cells, showed similar results. Significance was obtained for 
arachidonic acid, EPA and DHA (AA/PC20:4: 117.9% ± 3.5%, p = 0.002; EPA/PC20:5: 132.5% ± 5.9%, 
p < 0.001; DHA/PC22:6: 123.5% ± 3.9%, p < 0.001) (Table S3).  
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Figure 3. Effect of FA saturation on α-secretase activity. Phospholipids containing mono- 
or polyunsaturated FAs were exposed to (A) purified membranes of SH-SY5Y wt cells and 
living SH-SY5Y wt cells (B) purified membranes of human post mortem brains (C) 
purified α-secretase ADAM10 in the presence of human brain lipid extract. (A,B,C) 
Phospholipid concentration, determination of α-secretase activity, illustration and statistical 
significance as described for Figure 1. 
 
To analyze whether polyunsaturated FAs also increase α-secretase activity in the lipid environment 
of human brain, we incubated stearic acid (18:0), linolenic acid (18:3) and DHA (22:6), which is 
highly enriched in neuronal membranes [50–52], on purified membranes of human post mortem brains. 
As already observed for purified SH-SY5Y wt membranes and for living cells, linolenic acid showed 
non-significant alterations on α-secretase activity and DHA again significantly elevated α-secretase 
activity (DHA: 152.0% ± 17.4, p = 0.007) (Figure 3C, Table S3). Using purified ADAM10 enzyme for 
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the incubation with linolenic acid (PC18:3) and DHA (PC22:6) in the presence of human post mortem 
brain lipid extract, revealed that ADAM10 activity was significantly increased for both 
polyunsaturated FAs (PC18:3: 148.2% ± 4.2%, p < 0.001; DHA/PC22:6: 229.7% ± 2.7%, p < 0.001) 
(Figure 3C, Table S3). The extraordinary strong increase obtained with purified ADAM10 enzyme 
might be explained by the lack of other membrane proteins potentially involved in α-secretase 
regulation using brain lipid extract in contrast to purified membranes of human brains, which are not 
devoid of integral membrane proteins. One might speculate that such a protein could be e.g.,  
β-secretase BACE1, which competes with α-secretase for the initial cleavage of the substrate APP. In 
purified membranes of human post mortem brains BACE1 is still present and can cleave the APP 
substrate resulting in lower α-secretase cleavage compared to the α-secretase measurements using 
purified α-secretase ADAM10 and brain lipid extract where BACE1 is lacking and ADAM10 has not 
to compete with BACE1 for APP cleavage. In summary, all our results indicate that FA acyl chain 
saturation of phospholipids affects α-secretase activity with a more pronounced effect with an 
increasing number of double bonds within the hydrocarbon chains of the FAs. Arachidonic acid (four 
double bonds), EPA (five double bonds) and DHA (six double bonds) significantly increased  
α-secretase activity in living SH-SY5Y wt cells, whereas FAs with less than four double bonds 
revealed minor or no significant effects. This finding is in line with the recent study by Yang et al., 
showing increased levels of α-secreted APP (sAPPα) in the culture medium of differentiated  
SH-SY5Y cells exposed to arachidonic acid (20:4), EPA (20:5) and DHA (22:6) [53]. In the presence 
of DHA sAPPα secretion has also been shown to be increased in HEK cells expressing the substrate 
APP [54]. Additionally, stearic acid (18:0), oleic acid (18:1) and linoleic acid (18:2) showed no 
changes in sAPPα secretion in the study by Yang et al. [53], validating our results obtained by 
measuring α-secretase activity by the use of fluorogenic peptide. Furthermore, we validated our assay 
by using α-secretase inhibitors. Utilizing these inhibitors, α-secretase activity was decreased and for 
the non-cytotoxic α-secretase inhibitor GM6001, a reduction of sAPPα was also observed (Figure S4). 
However, it cannot be ruled out that the natural substrate, the intact APP protein, has different physical 
properties, e.g., affinity to the α-secretases, compared to the fluorogenic peptide and that these 
differences might influence the effect strength of phospholipids on α-secretase activity.  
Among the FAs analyzed, the main focus has to concentrate on DHA. DHA is highly enriched in 
neuronal cell membranes [50–52] and DHA levels have been found to be decreased in the brain and 
serum of AD patients and in AD post mortem brains [55–57]. Furthermore, several epidemiological 
studies indicate an inverse correlation between DHA intake and AD incidence or cognitive  
decline [58–61]. Importantly, DHA has also been shown to reduce Aβ generation in vitro and in 
animal models of AD [35,62–68]. These findings, together with our finding that DHA strongly increases 
non-amyloidogenic α-secretase activity in the lipid environment of human brain, indicate that DHA 
might have protective effects on AD by decreasing amyloidogenic and increasing non-amyloidogenic 
APP processing. 
2.4. Effect of the Double-Bond Position on α-Secretase Activity 
As we observed that FA chain length and the saturation grade of FAs influence α-secretase activity, 
we asked whether shifting the position of the double-bond within the monounsaturated FA oleic acid 
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PC18:1 might also affect α-secretase activity. Therefore, as a proof of principle, we analyzed PC18:1 
∆6-cis and PC18:1 ∆9-cis. Exposure of purified SH-SY5Y wt membranes to the ∆6-cis isomer 
revealed slightly—though significantly—increased α-secretase activity compared to PC18:1 ∆9-cis 
(PC18:1 ∆6-cis: 106.1% ± 1.0%, p = 0.041) (Figure 4A, Table S4), whereas no effect on α-secretase 
activity was obtained in living SH-SY5Y wt cells (Figure 4B, Table S4), thereby indicating that 
changing the position of the double-bond within a monounsaturated FA chain has no or only minor 
effects on non-amyloidogenic processing of APP. However, shifting the double-bond position further 
from the center of the membrane bilayer has been recently shown to affect γ-secretase cleavage [35]. 
In this study, γ-secretase activity was reduced in PC18:1∆6-cis compared to PC18:1∆9-cis.  
The observation that γ-secretase activity is affected more strongly by the position of the  
double-bond-induced kink within the phospholipid bilayer as α-secretase activity might be explained 
by the fact that γ-secretase cleaves the substrate APP within the middle of the phospholipid bilayer [69], 
whereas α-secretase cleaves APP within the extracellular/luminal domain. 
Figure 4. Effect of the double-bond position within the FA carbon chain on α-secretase 
activity. Phospholipids containing either FA 18:1∆9-cis or FA 18:1∆6-cis were incubated 
on (A) purified membranes of SH-SY5Y wt cells and (B) living SH-SY5Y wt cells;  
(A,B) Phospholipid concentration, determination of α-secretase activity, illustration and 
statistical significance as described for Figure 1. 
 
3. Experimental Section 
3.1. Chemicals and Reagents 
All chemicals used here were purchased from Sigma Aldrich (Taufkirchen, Germany), if not stated 
otherwise. Complete protease inhibitor cocktail was purchased from Roche (Grenzach-Wyhlen, 
Germany), Aspartate protease inhibitor, β-secretase inhibitor, and fluorogenic substrate were 
purchased from Calbiochem (Darmstadt, Germany). The following phospholipids were purchased 
from Avanti Polar Lipids (Alabaster, AL, USA), except for PC20:5 (Sigma, Taufkirchen, Germany): 
PC10:0—1,2-didecanoyl-sn-glycero-3-phosphocholine; PC12:0—1,2-dilauroyl-sn-glycero-3-














3.2. Cell Culture and Incubation with Phospholipids 
SH-SY5Ywt cells were cultivated in Dulbecco’s Modified Eagle’s Medium supplemented with 
10% FCS (PAN Biotech, Aidenbach, Germany) and non-essential amino acid solution. For incubation 
with phospholipids, SH-SY5Ywt cells were plated on a 96-well plate (Thermo Scientific, Waltham, 
MA, USA) and grown until confluency. Before incubation, cells were cultivated in medium containing 
0.1% FCS for 4 h. Incubation was carried out for 8 h + 16 h with 10 µM phospholipid. Final 
concentration of ethanol was less than 2‰, except PE- and PS-species (10‰).  
3.3. Detection of α-Secretase Activity in Vivo 
After incubation, SH-SY5Ywt cells were washed once with HEPES buffer, then 100 µL of cell 
imaging solution (140 mM NaCl2, 5 mM KCl, 8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES,  
pH 7.4) containing 10 µM phospholipid and 10 µM fluorogenic α-secretase substrate (sequence:  
Ac-RE-EDANS-VHHQK LVF-K-DABCYL-R-OH, Cat. No. 565767, Calbiochem, Darmstadt, 
Germany) was added. Fluorescence was measured continuously for 10,000 s with an excitation 
wavelength of 340 ± 10 nm and an emission wavelength of 490 ± 10 nm at 37 °C under light exclusion 
using a Safire2 Fluorometer (Tecan, Crailsheim, Germany) [23]. Enzyme activity kinetics are shown in 
the supplemental data section. 
3.4. Human Post Mortem Brains  
In total, nine human post mortem control brain samples were used. Brains were obtained from 
BrainNet (Munich, Germany). No CERAD status was assigned to 4 out of 5 brain samples. The fifth 
brain sample was assigned with CERAD status 0 (CERAD = the consortium to establish a registry for 
AD, standardizing procedures for the evaluation and diagnosis if patients with AD. A, B, C, 0 as 
described in http://cerad.mc.duke.edu/ [70]). 
3.5. Preparation of Purified Membranes  
SH-SY5Ywt cells and human post mortem brains were homogenized using a PotterS (Braun, 
Melsungen, Germany) at maximum speed (25 strokes) on ice. Protein concentration was measured 
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according to Smith et al. [71], as described in detail earlier [72]. Samples were adjusted to  
1 mg/mL, centrifuged at 900 rcf for 10 min at 4 °C and the obtained post-nuclear fractions were 
centrifuged at 55,000 rpm for 75 min at 4 °C. The pellet with purified membranes was resuspended 
using cannulaes (BD, Franklin Lakes, NJ, USA) with decreasing diameter in sucrose buffer (200 mM 
sucrose, 5 µM CaCl2, 5 µM ZnCl2) according to Grimm et al. [68]. 
3.6. Preparation of Human Brain Lipid Extract 
Lipids were extracted according to Bligh and Dyer [73] with minor modifications [72,74]. In brief, 
3.75 mL CHCl3:MeOH:HCl (37%) (1:2:0.06; v/v/v) was added to the sample and the mixture was 
vortexed for 1 h at room temperature (RT). Then, 1.25 mL CHCl3 was added and vortexed again for  
1 h at RT. Finally, 1.25 mL CHCl3 and 1.25 mL H2O were added and samples were vortexed for 
another 10 min before centrifugation at 5000 rpm for 10 min. The lower phase containing lipids was 
transferred to another glass tube and evaporated under nitrogen flow at 30 °C. Lipids were 
resuspended in 1 mL H2O and the extraction cycle described earlier was repeated before lipids were 
finally dissolved in ethanol.  
3.7. Determination of α-Secretase Activity and in Vitro Incubation  
Post-nuclear fractions of SH-SY5Ywt cells/human brain-purified membranes were incubated with 
25 µM/50 µM phospholipids for 15 min at 37 °C while shaking (Multireax, Heidolph Instruments, 
Schwabach, Germany). For determination of α-secretase activity, samples were adjusted to 100 µg of 
protein and 4 µM of fluorogenic α-secretase substrate was added. Fluorescence was measured as 
described above. Enzyme activity kinetics are shown in the supplemental data section. 
3.8. Determination of ADAM10 Purified Enzyme Activity  
Phospholipids (25 µM) were mixed with human brain lipid extract (5 µg lipid per 100 µL sucrose 
buffer) and incubated with 100 ng of ADAM10 purified enzyme (Cat. no. A9975, Sigma Aldrich, 
Taufkirchen, Germany) in sucrose buffer for 1 h at 4 °C while shaking, followed by sonification for  
15 min on ice. ADAM10 purified enzyme activity was determined as described above using the 
Infinite M1000 Pro Fluorometer. Enzyme activity kinetics are shown in the supplemental data section. 
3.9. Detection of Phospholipid Species in SH-SY5Ywt Cells and Human Post Mortem Brains  
Lipid extraction was performed as described above. One hundred microliter of each sample were 
spotted on thin layer chromatography plate and lipids were analyzed as described before [75].  
3.10. Mass Spectrometry Analysis 
To determine phospholipid distribution in post-nuclear fractions and membranes derived from 
human brains, phosphatidylcholine amounts were measured as described and validated in detail  
earlier [76]. For analysis, we used 20 µL of post-nuclear fractions and human brain lipid extract  
(for preparations see sections before). According to this method, additionally, the phospholipid uptake 
into living cells and membranes of SH-SY5Y cells was determined. 
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3.11. Statistical Analysis  
All quantified data presented here is based on an average of at least three independent experiments. 
Error bars represent standard deviation of the mean. Statistical significance was determined by 
ANOVA or two-tailed Student’s t-test; significance was set at * p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001. 
4. Conclusions 
Our results suggest that changes in the phospholipid composition of plasma membranes can 
influence α-secretase activity (Table 1) and might be involved in the development of AD. We found 
that α-secretase activity was significantly increased in the presence of FAs with short chain length and 
in the presence of polyunsaturated FAs with more than three double-bonds, thus suggesting that an 
increase in these phospholipids might have beneficial effects for AD.  
Table 1. Summary of the effects of different phospholipids on α-secretase activity.  
 SH-SY5Y membranes living SH-SY5Y cells purified ADAM10 human post mortem brain 
 Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) 
Effect of chain length    
PC 10:0 127.7 (2.2 n.s.) 124.8 (1.3 ***)   
PC 12:0 144.0 (9.3 **) 126.9 (1.3 ***) 132.0 (9.6 *) 141.9 (7.6 **) 
PC 14:0 128.0 (11.9 n.s.) 103.5 (1.2 n.s.)   
PC 16:0 99.8 (5.9 n.s.) 99.2 (1.3 n.s.)   
PC 18:0 100.0 (3.2) 100.0 (2.3 n.s.) 100.0 (6.4) 100.0 (5.7) 
PC 20:0 102.3 (0.5 n.s.) 98.8 (1.9 n.s.)   
PC 22:0 98.8 (1.9 n.s.) 100.1 (2.3 n.s.)   
PC 24:0 101.7 (1.5 n.s.) 107.8 (2.2 n.s.)   
 Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) 
Effect of headgroup    
PC 12:0 100.0 (0.7) 100.0 (1.1)  100.0 (4.5) 
PE 12:0 98.5 (1.3 n.s.) 93.6 (2.8 n.s.)  109.2 (3.1 n.s.) 
PS 12:0 93.4 (2.5 n.s.) 83.8 (1.6 **)  104.9 (3.7 n.s.) 
PC 14:0 100.0 (1.9) 100.0 (1.1)  100.0 (10.9) 
PE 14:0 101.0 (1.5 n.s.) 105.0 (4.0 n.s.)  105.7 (3.6 n.s.) 
PS 14:0 116.2 (3.1 ***) 96.6 (2.0 n.s.)  104.7 (12.2 n.s.) 
 Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) 
Effect of saturation    
PC 18:0 100.0 (1.2) 100.0 (2.3) 100.0 (4.8) 100.0 (3.1) 
PC 18:1 102.0 (1.5 n.s.) 110.3 (4.3 n.s.)   
PC 18:2 97.1 (2.1 n.s.) 115.0 (6.6 n.s.)   
PC 18:3 98.2 (2.0 n.s.) 117.4 (2.3 n.s.) 148.2 (4.2 ***) 106.3 (2.7 n.s.) 
PC 20:4 104.2 (4.8 n.s.) 124.7 (2.0 **)   
PC 20:5 123.1 (7.6 **) 140.1 (14.2 ***)   
PC 22:6 108.6 (2.6 n.s.) 136.8 (2.2 ***) 229.7 (2.7 ***) 152.0 (17.4 **) 
 Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) Mean % (SEM % +/− Sign.) 
Effect of double-bond position    
PC 18:1D9 100.0 (1.8) 100.0 (4.4)   
PC 18:1D6 106.1 (1.0 *) 101.7 (4.5 n.s.)   
Asterisks show the statistical significance (* p ≤ 0.05; ** p ≤ 0.01 and *** p ≤ 0.001, n.s. not significant). 




We thank Inge Tomic for technical assistance. The research leading to these results has received 
fundings from the EU FP7 project LipiDiDiet, Grant Agreement No 211696 (TH), the DFG (TH), the 
Bundesministerium für Bildung, Forschung, Wissenschaft und Technologie via NGFNplus and KNDD 
(TH), the HOMFOR 2009 (MG, TH) and the HOMFORexzellent 2011 (MG) (Saarland University 
research grants). We thank Tecan Ltd. for their technical support. 
Conflict of Interest 
The authors declare no conflict of interest. 
References 
1. Masters, C.L.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. 
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 
1985, 82, 4245–4249. 
2. Selkoe, D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2001, 81, 741–766. 
3. Dyrks, T.; Weidemann, A.; Multhaup, G.; Salbaum, J.M.; Lemaire, H.G.; Kang, J.; Muller-Hill, B.; 
Masters, C.L.; Beyreuther, K. Identification, transmembrane orientation and biogenesis of the 
amyloid A4 precursor of Alzheimer’s disease. EMBO J. 1988, 7, 949–957. 
4. Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; 
Ross, S.; Amarante, P.; Loeloff, R.; et al. Beta-secretase cleavage of Alzheimer’s amyloid 
precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735–741. 
5. Sinha, S.; Anderson, J.P.; Barbour, R.; Basi, G.S.; Caccavello, R.; Davis, D.; Doan, M.;  
Dovey, H.F.; Frigon, N.; Hong, J.; et al. Purification and cloning of amyloid precursor protein 
beta-secretase from human brain. Nature 1999, 402, 537–540. 
6. Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B.L.; 
Lieberburg, I.; Koo, E.H.; Schenk, D.; Teplow, D.B.; et al. Amyloid beta-peptide is produced by 
cultured cells during normal metabolism. Nature 1992, 359, 322–325. 
7. Shoji, M.; Golde, T.E.; Ghiso, J.; Cheung, T.T.; Estus, S.; Shaffer, L.M.; Cai, X.D.; McKay, 
D.M.; Tintner, R.; Frangione, B.; et al. Production of the Alzheimer amyloid beta protein by 
normal proteolytic processing. Science 1992, 258, 126–129. 
8. Herreman, A.; Serneels, L.; Annaert, W.; Collen, D.; Schoonjans, L.; de Strooper, B. Total 
inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell. Biol. 
2000, 2, 461–462. 
9. Takasugi, N.; Tomita, T.; Hayashi, I.; Tsuruoka, M.; Niimura, M.; Takahashi, Y.; Thinakaran, G.; 
Iwatsubo, T. The role of presenilin cofactors in the gamma-secretase complex. Nature 2003, 422, 
438–441. 
10. Kimberly, W.T.; LaVoie, M.J.; Ostaszewski, B.L.; Ye, W.; Wolfe, M.S.; Selkoe, D.J.  
Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and 
Pen-2. Proc. Natl. Acad. Sci. USA 2003, 100, 6382–6387. 
Int. J. Mol. Sci. 2013, 14 5894 
 
 
11. Duering, M.; Grimm, M.O.; Grimm, H.S.; Schroder, J.; Hartmann, T. Mean age of onset in familial 
Alzheimer’s disease is determined by amyloid beta 42. Neurobiol. Aging 2005, 26, 785–788. 
12. Haass, C.; Hung, A.Y.; Schlossmacher, M.G.; Teplow, D.B.; Selkoe, D.J. Beta-Amyloid peptide 
and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. 1993, 268, 
3021–3024. 
13. Lichtenthaler, S.F. Alpha-secretase in Alzheimer’s disease: Molecular identity, regulation and 
therapeutic potential. J. Neurochem. 2011, 116, 10–21. 
14. Buxbaum, J.D.; Liu, K.N.; Luo, Y.; Slack, J.L.; Stocking, K.L.; Peschon, J.J.; Johnson, R.S.; 
Castner, B.J.; Cerretti, D.P.; Black, R.A. Evidence that tumor necrosis factor alpha converting 
enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein 
precursor. J. Biol. Chem. 1998, 273, 27765–27767. 
15. Lammich, S.; Kojro, E.; Postina, R.; Gilbert, S.; Pfeiffer, R.; Jasionowski, M.; Haass, C.; 
Fahrenholz, F. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid 
precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. USA 1999, 96, 3922–3927. 
16. Koike, H.; Tomioka, S.; Sorimachi, H.; Saido, T.C.; Maruyama, K.; Okuyama, A.;  
Fujisawa-Sehara, A.; Ohno, S.; Suzuki, K.; Ishiura, S. Membrane-anchored metalloprotease 
MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. 
Biochem. J. 1999, 343, 371–375. 
17. Allinson, T.M.; Parkin, E.T.; Turner, A.J.; Hooper, N.M. ADAMs family members as amyloid 
precursor protein alpha-secretases. J. Neurosci. Res. 2003, 74, 342–352. 
18. Hartmann, T.; Kuchenbecker, J.; Grimm, M.O. Alzheimer’s disease: The lipid connection.  
J. Neurochem. 2007, 103, 159–170. 
19. Osenkowski, P.; Ye, W.; Wang, R.; Wolfe, M.S.; Selkoe, D.J. Direct and potent regulation of 
gamma-secretase by its lipid microenvironment. J. Biol. Chem. 2008, 283, 22529–22540. 
20. Grimm, M.O.; Rothhaar, T.L.; Hartmann, T. The role of APP proteolytic processing in lipid 
metabolism. Exp. Brain Res. 2012, 217, 365–375. 
21. Lemkul, J.A.; Bevan, D.R. Lipid composition influences the release of Alzheimer’s amyloid  
beta-peptide from membranes. Protein Sci. 2011, 20, 1530–1545. 
22. Grimm, M.O.; Rothhaar, T.L.; Grösgen, S.; Burg, V.K.; Hundsdorfer, B.; Haupenthal, V.J.;  
Friess, P.; Kins, S.; Grimm, H.S.; Hartmann, T. Trans fatty acids enhance amyloidogenic processing 
of the Alzheimer amyloid precursor protein (APP). J. Nutr. Biochem. 2012, 23, 1214–1223. 
23. Rothhaar, T.L.; Grosgen, S.; Haupenthal, V.J.; Burg, V.K.; Hundsdorfer, B.; Mett, J.; 
Riemenschneider, M.; Grimm, H.S.; Hartmann, T.; Grimm, M.O. Plasmalogens inhibit APP 
processing by directly affecting gamma-secretase activity in Alzheimer’s disease. Sci. World J. 
2012, 2012, 141240. 
24. Marenchino, M.; Williamson, P.T.; Murri, S.; Zandomeneghi, G.; Wunderli-Allenspach, H.; 
Meier, B.H.; Kramer, S.D. Dynamics and Cleavability at the alpha-cleavage site of  
APP(684–726) in different lipid environments. Biophys. J. 2008, 95, 1460–1473. 
25. Barrett, P.J.; Song, Y.; van Horn, W.D.; Hustedt, E.J.; Schafer, J.M.; Hadziselimovic, A.;  
Beel, A.J.; Sanders, C.R. The amyloid precursor protein has a flexible transmembrane domain and 
binds cholesterol. Science 2012, 336, 1168–1171. 
Int. J. Mol. Sci. 2013, 14 5895 
 
 
26. Simons, M.; Keller, P.; de Strooper, B.; Beyreuther, K.; Dotti, C.G.; Simons, K. Cholesterol 
depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 
1998, 95, 6460–6464. 
27. Grösgen, S.; Grimm, M.O.; Friess, P.; Hartmann, T. Role of amyloid beta in lipid homeostasis. 
Biochim. Biophys. Acta 2010, 1801, 966–974. 
28. Grimm, M.O.; Grimm, H.S.; Tomic, I.; Beyreuther, K.; Hartmann, T.; Bergmann, C. Independent 
inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol 
levels. J. Biol. Chem. 2008, 283, 11302–11311. 
29. Grimm, M.O.; Grimm, H.S.; Patzold, A.J.; Zinser, E.G.; Halonen, R.; Duering, M.; Tschape, J.A.; 
De Strooper, B.; Muller, U.; Shen, J.; et al. Regulation of cholesterol and sphingomyelin 
metabolism by amyloid-beta and presenilin. Nat. Cell. Biol. 2005, 7, 1118–1123. 
30. Zha, Q.; Ruan, Y.; Hartmann, T.; Beyreuther, K.; Zhang, D. GM1 ganglioside regulates the 
proteolysis of amyloid precursor protein. Mol. Psychiatry 2004, 9, 946–952. 
31. Grimm, M.O.; Zinser, E.G.; Grösgen, S.; Hundsdorfer, B.; Rothhaar, T.L.; Burg, V.K.;  
Kaestner, L.; Bayer, T.A.; Lipp, P.; Muller, U.; et al. Amyloid precursor protein (APP) mediated 
regulation of ganglioside homeostasis linking Alzheimer’s disease pathology with ganglioside 
metabolism. PLoS One 2012, 7, e34095. 
32. Svennerholm, L.; Gottfries, C.G. Membrane lipids, selectively diminished in Alzheimer brains, 
suggest synapse loss as a primary event in early-onset form (type I) and demyelination in  
late-onset form (type II). J. Neurochem. 1994, 62, 1039–1047. 
33. Wells, K.; Farooqui, A.A.; Liss, L.; Horrocks, L.A. Neural membrane phospholipids in Alzheimer 
disease. Neurochem. Res. 1995, 20, 1329–1333. 
34. Prasad, M.R.; Lovell, M.A.; Yatin, M.; Dhillon, H.; Markesbery, W.R. Regional membrane 
phospholipid alterations in Alzheimer’s disease. Neurochem. Res. 1998, 23, 81–88. 
35. Holmes, O.; Paturi, S.; Ye, W.; Wolfe, M.S.; Selkoe, D.J. Effects of membrane lipids on the 
activity and processivity of purified gamma-secretase. Biochemistry 2012, 51, 3565–3575. 
36. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature 1997, 387, 569–572. 
37. Vetrivel, K.S.; Thinakaran, G. Membrane rafts in Alzheimer’s disease beta-amyloid production. 
Biochim. Biophys. Acta 2010, 1801, 860–867. 
38. Riddell, D.R.; Christie, G.; Hussain, I.; Dingwall, C. Compartmentalization of beta-secretase 
(Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr. Biol. 2001, 11, 1288–1293. 
39. Vetrivel, K.S.; Cheng, H.; Lin, W.; Sakurai, T.; Li, T.; Nukina, N.; Wong, P.C.; Xu, H.; 
Thinakaran, G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome 
membranes. J. Biol. Chem. 2004, 279, 44945–44954. 
40. Vetrivel, K.S.; Cheng, H.; Kim, S.H.; Chen, Y.; Barnes, N.Y.; Parent, A.T.; Sisodia, S.S.; 
Thinakaran, G. Spatial segregation of gamma-secretase and substrates in distinct membrane 
domains. J. Biol. Chem. 2005, 280, 25892–25900. 
41. Koumanov, K.S.; Tessier, C.; Momchilova, A.B.; Rainteau, D.; Wolf, C.; Quinn, P.J. 
Comparative lipid analysis and structure of detergent-resistant membrane raft fractions isolated 
from human and ruminant erythrocytes. Arch. Biochem. Biophys. 2005, 434, 150–158. 
Int. J. Mol. Sci. 2013, 14 5896 
 
 
42. Kojro, E.; Gimpl, G.; Lammich, S.; Marz, W.; Fahrenholz, F. Low cholesterol stimulates the 
nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 
2001, 98, 5815–5820. 
43. Ehehalt, R.; Keller, P.; Haass, C.; Thiele, C.; Simons, K. Amyloidogenic processing of the 
Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160, 113–123. 
44. Parr-Sturgess, C.A.; Rushton, D.J.; Parkin, E.T. Ectodomain shedding of the Notch ligand 
Jagged1 is mediated by ADAM17, but is not a lipid-raft-associated event. Biochem. J. 2010, 432, 
283–294. 
45. Kuhn, P.H.; Wang, H.; Dislich, B.; Colombo, A.; Zeitschel, U.; Ellwart, J.W.; Kremmer, E.; 
Rossner, S.; Lichtenthaler, S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase 
of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29, 3020–3032. 
46. Stokes, C.E.; Hawthorne, J.N. Reduced phosphoinositide concentrations in anterior temporal 
cortex of Alzheimer-diseased brains. J. Neurochem. 1987, 48, 1018–1021. 
47. Nitsch, R.M.; Blusztajn, J.K.; Pittas, A.G.; Slack, B.E.; Growdon, J.H.; Wurtman, R.J.  
Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA 1992, 89, 
1671–1675. 
48. Nesic, I.; Guix, F.X.; Vennekens, K.; Michaki, V.; van Veldhoven, P.P.; Feiguin, F.;  
de Strooper, B.; Dotti, C.G.; Wahle, T. Alterations in phosphatidylethanolamine levels affect the 
generation of Abeta. Aging Cell 2012, 11, 63–72. 
49. Escriba, P.V.; Gonzalez-Ros, J.M.; Goni, F.M.; Kinnunen, P.K.; Vigh, L.; Sanchez-Magraner, L.; 
Fernandez, A.M.; Busquets, X.; Horvath, I.; Barcelo-Coblijn, G. Membranes: A meeting point for 
lipids, proteins and therapies. J. Cell. Mol. Med. 2008, 12, 829–875. 
50. Bazan, N.G.; Scott, B.L. Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid 
in rod photoreceptor cells of the retina and at synapses. Ups. J. Med. Sci. Suppl. 1990, 48, 97–107. 
51. Ansari, K.A.; Shoeman, D.W. Arachidonic and docosahexanoic acid content of bovine brain 
myelin: Implications for the pathogenesis of multiple sclerosis. Neurochem. Res. 1990, 15, 7–11. 
52. Horrocks, L.A.; Farooqui, A.A. Docosahexaenoic acid in the diet: Its importance in maintenance 
and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 2004, 70, 
361–372. 
53. Yang, X.; Sheng, W.; Sun, G.Y.; Lee, J.C. Effects of fatty acid unsaturation numbers on 
membrane fluidity and alpha-secretase-dependent amyloid precursor protein processing. 
Neurochem. Int. 2011, 58, 321–329. 
54. Eckert, G.P.; Chang, S.; Eckmann, J.; Copanaki, E.; Hagl, S.; Hener, U.; Muller, W.E.; Kogel, D. 
Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP 
processing. Biochim. Biophys. Acta 2011, 1808, 236–243. 
55. Soderberg, M.; Edlund, C.; Kristensson, K.; Dallner, G. Fatty acid composition of brain 
phospholipids in aging and in Alzheimer’s disease. Lipids 1991, 26, 421–425. 
56. Tully, A.M.; Roche, H.M.; Doyle, R.; Fallon, C.; Bruce, I.; Lawlor, B.; Coakley, D.; Gibney, M.J. 
Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: A case-control 
study. Br. J. Nutr. 2003, 89, 483–489. 
Int. J. Mol. Sci. 2013, 14 5897 
 
 
57. Cunnane, S.C.; Schneider, J.A.; Tangney, C.; Tremblay-Mercier, J.; Fortier, M.; Bennett, D.A.; 
Morris, M.C. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s 
disease. J. Alzheimers Dis. 2012, 29, 691–697. 
58. Barberger-Gateau, P.; Letenneur, L.; Deschamps, V.; Peres, K.; Dartigues, J.F.; Renaud, S.  
Fish, meat, and risk of dementia: Cohort study. Br. Med. J. 2002, 325, 932–933. 
59. Morris, M.C.; Evans, D.A.; Bienias, J.L.; Tangney, C.C.; Bennett, D.A.; Wilson, R.S.;  
Aggarwal, N.; Schneider, J. Consumption of fish and n-3 fatty acids and risk of incident 
Alzheimer disease. Arch. Neurol. 2003, 60, 940–946. 
60. Schaefer, E.J.; Bongard, V.; Beiser, A.S.; Lamon-Fava, S.; Robins, S.J.; Au, R.; Tucker, K.L.; 
Kyle, D.J.; Wilson, P.W.; Wolf, P.A. Plasma phosphatidylcholine docosahexaenoic acid content 
and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch. Neurol. 2006, 
63, 1545–1550. 
61. Van Gelder, B.M.; Tijhuis, M.; Kalmijn, S.; Kromhout, D. Fish consumption, n-3 fatty acids, and 
subsequent 5-y cognitive decline in elderly men: The Zutphen Elderly Study. Am. J. Clin. Nutr. 
2007, 85, 1142–1147. 
62. Lukiw, W.J.; Cui, J.G.; Marcheselli, V.L.; Bodker, M.; Botkjaer, A.; Gotlinger, K.; Serhan, C.N.; 
Bazan, N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival 
and Alzheimer disease. J. Clin. Invest. 2005, 115, 2774–2783. 
63. Perez, S.E.; Berg, B.M.; Moore, K.A.; He, B.; Counts, S.E.; Fritz, J.J.; Hu, Y.S.; Lazarov, O.;  
Lah, J.J.; Mufson, E.J. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 
transgenic mice: Possible gender effects. J. Neurosci. Res. 2010, 88, 1026–1040. 
64. Oksman, M.; Iivonen, H.; Hogyes, E.; Amtul, Z.; Penke, B.; Leenders, I.; Broersen, L.;  
Lutjohann, D.; Hartmann, T.; Tanila, H. Impact of different saturated fatty acid, polyunsaturated 
fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic 
mice. Neurobiol. Dis. 2006, 23, 563–572. 
65. Calon, F.; Lim, G.P.; Yang, F.; Morihara, T.; Teter, B.; Ubeda, O.; Rostaing, P.; Triller, A.; 
Salem, N., Jr.; Ashe, K.H.; et al. Docosahexaenoic acid protects from dendritic pathology in an 
Alzheimer’s disease mouse model. Neuron 2004, 43, 633–645. 
66. Hooijmans, C.R.; Rutters, F.; Dederen, P.J.; Gambarota, G.; Veltien, A.; van Groen, T.;  
Broersen, L.M.; Lutjohann, D.; Heerschap, A.; Tanila, H.; et al. Changes in cerebral blood 
volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid 
(DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol. Dis. 2007, 28, 16–29. 
67. Cole, G.M.; Ma, Q.L.; Frautschy, S.A. Omega-3 fatty acids and dementia. Prostaglandins Leukot 
Essent Fatty Acids 2009, 81, 213–221. 
68. Grimm, M.O.; Kuchenbecker, J.; Grösgen, S.; Burg, V.K.; Hundsdorfer, B.; Rothhaar, T.L.; 
Friess, P.; de Wilde, M.C.; Broersen, L.M.; Penke, B.; et al. Docosahexaenoic acid reduces 
amyloid beta production via multiple pleiotropic mechanisms. J. Biol. Chem. 2011, 286,  
14028–14039. 
69. Grziwa, B.; Grimm, M.O.; Masters, C.L.; Beyreuther, K.; Hartmann, T.; Lichtenthaler, S.F.  
The transmembrane domain of the amyloid precursor protein in microsomal membranes is on 
both sides shorter than predicted. J. Biol. Chem. 2003, 278, 6803–6808. 
Int. J. Mol. Sci. 2013, 14 5898 
 
 
70. Duyckaerts, C.; Hauw, J.J. Diagnosis and staging of Alzheimer disease. Neurobiol. Aging 1997, 
18, S33–S42. 
71. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; 
Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using 
bicinchoninic acid. Anal. Biochem. 1985, 150, 76–85. 
72. Grimm, M.O.; Grösgen, S.; Rothhaar, T.L.; Burg, V.K.; Hundsdorfer, B.; Haupenthal, V.J.;  
Friess, P.; Muller, U.; Fassbender, K.; Riemenschneider, M.; et al. Intracellular APP domain 
regulates serine-palmitoyl-coa transferase expression and is affected in Alzheimer’s disease.  
Int. J. Alzheimers Dis. 2011, 2011, 695413. 
73. Bligh, E.G.; Dyer, W.J. A rapid method of total lipid extraction and purification. Can. J.  
Biochem. Physiol. 1959, 37, 911–917. 
74. Grimm, M.O.; Kuchenbecker, J.; Rothhaar, T.L.; Grösgen, S.; Hundsdorfer, B.; Burg, V.K.; 
Friess, P.; Muller, U.; Grimm, H.S.; Riemenschneider, M.; et al. Plasmalogen synthesis is 
regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing 
and is affected in Alzheimer’s disease. J. Neurochem. 2011, 116, 916–925. 
75. Ruiz, J.I.; Ochoa, B. Quantification in the subnanomolar range of phospholipids and neutral lipids 
by monodimensional thin-layer chromatography and image analysis. J. Lipid Res. 1997, 38, 
1482–1489. 
76. Grimm, M.O.; Grösgen, S.; Riemenschneider, M.; Tanila, H.; Grimm, H.S.; Hartmann, T.  
From brain to food: Analysis of phosphatidylcholins, lyso-phosphatidylcholins and 
phosphatidylcholin-plasmalogens derivates in Alzheimer’s disease human post mortem brains and 
mice model via mass spectrometry. J. Chromatogr. A 2011, 1218, 7713–7722. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
